CMS finalizes rule cutting federal Medicaid funding for youth gender-affirming care

The Trump administration’s campaign to restrict transgender health services for minors has encountered multiple judicial setbacks, yet a new regulation from the Centers for Medicare and Medicaid Services may prove more resilient. Announced Tuesday, the rule bars federal Medicaid and Children’s Health Insurance Program funds from paying for gender-affirming medication or surgery for anyone under 18, and for CHIP recipients under 19, with a six-month tapering period that extends coverage until April 2027.

After receiving nearly 35,000 public comments, the agency cited its independent legal authority and referenced precedents such as the Hyde Amendment and a 1976 sterilization regulation to justify the action. Legal analysts expect challenges, including a lawsuit announced by Massachusetts’ attorney general, but note the rule’s careful framing to survive court review. States can still allocate their own Medicaid dollars for gender-affirming care, yet advocates warn that thousands of low-income transgender youths could lose essential treatment. The decision reflects a broader ideological battle and may set the stage for further, more restrictive measures the administration seeks to impose on providers of gender-affirming care.